Company Performance Metrics
- Louis Bowen: Founder and Executive Chairman
Cindy Tsang: Director, Business Development
Pacific GeneTech develops and commercializes first-in-class or best-in-class vaccines for areas of high unmet or underserved needs in food safety and livestock animal health. The global animal vaccine market is a valuable opportunity and is expected to reach US$20.6 billion by 2021. Livestock illness can lead to human infections, poor feed
conversion, or loss of animals, making it a significant economic burden to producers.
Founded in 2009, Pacific GeneTech focuses on developing and commercializing vaccines for the livestock industry through their proprietary Aegis platform which have broad cross-protection. In 2012, they acquired the exclusive global rights to Hercules Adjuvant Delivery System to enhance Aegis developed vaccines and explore partnership opportunities for other vaccine products. Pacific GeneTech has out-licensed two of its leading poultry vaccines addressing economically important gastro-intestinal pathogens and has out-licensed its Hercules adjuvant for use in third-party vaccines. Vaccines for other pathogens and animal species are under development. Pacific GeneTech is developing other applications for its Hercules adjuvant delivery system. Pacific GeneTech, through its affiliate company, PGTx, has commenced programs with collaborators addressing human dysentery.
